As Chinese exports, from electric vehicles to e-commerce goods, reshape Latin American markets, governments and industries grapple with the dual pressures of affordable consumer goods and strained local manufacturing, forcing a delicate recalibration of trade policies and regional alliances.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
Authorities in Pima County are conducting an extensive search for Nancy Guthrie, 84, the mother of 'Today' show co-host Savannah Guthrie, who was reported missing from her Tucson-area home under circumstances described as 'very concerning.'
The global payments giant reported a 15% surge in net revenue and processed a record 69.4 billion transactions in its fiscal first quarter, signaling resilient consumer confidence and a rebound from previous quarters.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
Afya Ltd., a leading medical education group in Brazil, is demonstrating robust financial health with a rising Return on Capital Employed (ROCE) and significant capital expansion. While its stock has faced headwinds, the underlying operational metrics suggest a company efficiently reinvesting for growth, presenting a potential opportunity for value-focused investors.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Morris Chang, the 94-year-old founder of Taiwan Semiconductor Manufacturing Co., made his first public appearance in over a year at a private dinner in Taipei with Nvidia CEO Jensen Huang. The meeting, which ended months of speculation about Chang's health and public role, also served as a platform to reaffirm TSMC's central position in the global chip supply chain.
Amid a cautiously recovering Eurozone economy, dividend-paying stocks are gaining attention from investors seeking reliable income and a buffer against market volatility. We analyze three standout European companies offering compelling yield and value.
While OceanFirst Financial (OCFC) has kept pace with the market, analysts highlight concerns over its weak net interest income growth, modest earnings expansion, and a projected decline in tangible book value. The search for value shifts focus elsewhere.
As a Utah murder trial resumes, defense attorneys are pressing to remove the entire county prosecutor's office from the case, arguing the presence of a lead attorney's child at the crime scene creates an untenable conflict. Legal experts weigh the high bar for such motions.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
Audius SE (FRA:3ITN) shares jumped 13% last week, prompting a closer look at whether the rally is backed by the company's financial health or driven by broader market sentiment.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
Certified financial planner and popular financial educator Kevin Lum outlines a crucial mindset shift for those nearing or in retirement, urging them to move beyond accumulation and toward purposeful living.
Italian Prime Minister Giorgia Meloni and German Chancellor Friedrich Merz have signed a landmark partnership pact in Rome, signaling a potential shift in the European Union's traditional Franco-German power center. The accord, focusing on defense, migration, and trade, comes as France grapples with political instability and a weakened presidency.
Snapchat has disabled hundreds of thousands of accounts belonging to users under 16 in Australia under new social media laws, but warns the legislation contains 'significant gaps' that may allow some minors to bypass protections.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
